Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
About Carisma Therapeutics Inc.
Carisma Therapeutics Inc. (NASDAQ: CARM) is a clinical-stage biopharmaceutical company pioneering the development of transformative immunotherapies through its proprietary chimeric antigen receptor macrophage (CAR-M) and monocyte cell engineering platform. Headquartered in Philadelphia, Pennsylvania, Carisma is at the forefront of advancing next-generation cell therapies to address critical unmet medical needs in oncology, fibrosis, and autoimmune diseases.
Innovative Cell Therapy Platform
Carisma's proprietary platform focuses on engineering macrophages and monocytes, a subgroup of white blood cells critical to both the innate and adaptive immune responses. Unlike traditional CAR-T therapies, which target lymphocytes, Carisma's approach leverages the unique properties of myeloid cells to infiltrate solid tumors, modulate the tumor microenvironment, and address antigen heterogeneity. This innovative platform has enabled the development of both ex vivo (outside the body) and in vivo (inside the body) therapies, positioning the company as a leader in macrophage-based immunotherapy.
Core Therapeutic Areas
- Oncology: Carisma's lead programs focus on addressing HER2-overexpressing solid tumors through CAR-Macrophage and CAR-Monocyte therapies. These programs aim to overcome the limitations of existing cell therapies by enhancing tumor infiltration, persistence, and manufacturing efficiency.
- Fibrosis: The company is advancing preclinical programs targeting liver fibrosis, including conditions like metabolic-associated steatohepatitis (MASH). Engineered macrophages in these programs aim to reduce fibrosis and inflammation while restoring key cellular processes.
- Autoimmune Diseases: Through an expanded collaboration with Moderna, Carisma is exploring the potential of in vivo macrophage engineering to address autoimmune conditions, leveraging its deep expertise in myeloid biology.
Strategic Collaborations
Carisma has established a strategic partnership with Moderna, Inc., combining Carisma's expertise in macrophage engineering with Moderna's mRNA and lipid nanoparticle (LNP) platform. This collaboration has yielded promising in vivo CAR-M candidates targeting oncology and autoimmune diseases, including a development candidate for hepatocellular carcinoma (HCC). These partnerships underscore Carisma's commitment to innovation and scalability.
Market Position and Competitive Edge
In a competitive landscape dominated by CAR-T and other immune cell therapies, Carisma differentiates itself with its focus on macrophages and monocytes. This approach addresses key challenges in treating solid tumors, such as tumor microenvironment immunosuppression and antigen heterogeneity. Additionally, its pivot to in vivo therapies represents a strategic shift toward off-the-shelf solutions, potentially reducing manufacturing complexities and costs.
Operational Focus and Future Outlook
Carisma recently reprioritized its pipeline to focus on high-potential in vivo programs in oncology, fibrosis, and autoimmune diseases. This strategic realignment, coupled with a streamlined workforce, reflects the company's commitment to operational efficiency and long-term innovation. With multiple preclinical and clinical milestones anticipated in the coming years, Carisma is well-positioned to deliver transformative therapies that redefine treatment paradigms.
Conclusion
Carisma Therapeutics Inc. represents a paradigm shift in cell therapy, leveraging macrophage and monocyte engineering to tackle some of the most challenging diseases. Through its innovative platform, strategic collaborations, and focused pipeline, Carisma is poised to make a significant impact in the fields of oncology, fibrosis, and autoimmune diseases, offering hope to patients with limited treatment options.
Carisma Therapeutics Inc. (Nasdaq: CARM) has expanded its collaboration with Moderna, Inc. (Nasdaq: MRNA) to develop in vivo CAR-M therapies for autoimmune diseases. This expansion builds on their successful pre-clinical oncology data and includes the nomination of two autoimmune disease targets by Moderna. Carisma will receive research funding and is eligible for milestone and royalty payments.
The collaboration leverages Carisma's proprietary CAR-M technology and Moderna's mRNA/LNP platform. Carisma will handle discovery and optimization of development candidates, while Moderna will lead clinical development and commercialization. This partnership aims to revolutionize treatments for autoimmune conditions, expanding the potential of CAR-M technology beyond oncology.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, has announced its participation in four upcoming healthcare conferences. Steven Kelly, President and CEO, will represent the company at these events:
1. Baird 2024 Global Healthcare Conference on September 10 at 12:50 PM ET in New York, NY
2. H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 1:30 PM ET in New York, NY
3. Chardan's 8th Annual Genetic Medicines Conference on September 30 at 4:00 PM ET in New York, NY
4. The Cell & Gene Meeting on the Mesa on October 7 at 9:30 AM MST in Phoenix, AZ
Live webcasts of these presentations will be available on Carisma's Investor Events webpage, with replays archived for a time after each event.
Carisma Therapeutics (Nasdaq: CARM) reported Q2 2024 financial results and business highlights. Key points include:
- Initial data for CT-0525, their lead anti-HER2 product, expected by year-end 2024
- Nomination of a liver fibrosis development candidate expected in Q1 2025
- First in vivo CAR-M candidate targeting Glypican-3 for hepatocellular carcinoma nominated under Moderna collaboration
- Cash position of $40.4 million, plus $2.0 million from Moderna, expected to fund operations into Q3 2025
- Q2 2024 net loss of $11.2 million, compared to $19.9 million in Q2 2023
- R&D expenses decreased to $15.3 million from $18.5 million year-over-year
- G&A expenses slightly decreased to $5.6 million from $6.0 million year-over-year
Carisma Therapeutics (Nasdaq: CARM) has announced an upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. The event will take place in San Diego, California, from November 15 to 19, 2024.
The presentation, titled 'Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models', is scheduled for November 17, 2024, from 8:00 am to 5:00 pm. It falls under the session 'MASLD/MASH - Therapeutics: New Agents' and has been assigned the publication number 3214.
Carisma Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing innovative immunotherapies. The poster will be available on the company's website in the 'Publications' section following the start of the poster session.
Carisma Therapeutics Inc. (Nasdaq: CARM) has expanded its Scientific Advisory Board (SAB) by appointing two renowned key opinion leaders in liver fibrosis, Dr. Scott Friedman and Dr. Ira Tabas. This strategic move aims to bolster Carisma's program in developing innovative treatments for advanced liver disease. Steven Kelly, President and CEO of Carisma, expressed enthusiasm about leveraging the extensive experience and groundbreaking research of these experts to enhance the company's efforts in creating engineered macrophage therapies. The addition of these prominent figures to the SAB is expected to provide valuable insights and expertise as Carisma continues its mission to develop transformative treatments for patients.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the appointment of Marella Thorell and Dr. David Scadden to its Board of Directors, effective June 30, 2024. This decision coincides with the resignation of Regina Hodits and Björn Odlander due to other professional commitments. Carisma's leadership highlighted the vast experience that Thorell and Scadden bring to the company, which is expected to enhance the advancement of its cell therapy platform focused on engineered macrophages. The company expressed gratitude to the outgoing board members for their contributions.
Carisma Therapeutics (Nasdaq: CARM) has announced the nomination of the first in vivo CAR-M development candidate, targeting Glypican-3 (GPC3), under its collaboration with Moderna. This candidate is designed to treat solid tumors, including hepatocellular carcinoma (HCC), the fastest-rising cause of cancer-related death in the U.S.
This nomination triggers a $2 million milestone payment to Carisma and leverages Carisma's expertise in engineering CAR-M with Moderna's mRNA and lipid nanoparticle platform. Pre-clinical data show the candidate can create CAR-M directly in vivo, redirecting myeloid cells to attack cancer cells.
The program advances under the 2022 strategic collaboration agreement between Carisma and Moderna, aiming to discover and commercialize in vivo CAR-M therapeutics. Moderna has also nominated four additional undisclosed oncology research targets under this collaboration.
Carisma Therapeutics (Nasdaq: CARM) announced that the FDA granted Fast Track designation for CT-0525, a gene-modified cellular therapy for HER2-overexpressing solid tumors. This designation aims to expedite the development and review of therapies addressing serious conditions with unmet medical needs. The Phase 1 clinical trial is ongoing, focusing on safety, tolerability, and manufacturing feasibility. Initial data is expected by the end of 2024. The trial targets patients with advanced or metastatic solid tumors unresponsive to standard therapies.
Carisma Therapeutics, a clinical-stage biopharmaceutical company specializing in innovative immunotherapies, has announced its participation in the Stifel 2024 Cell Therapy Forum.
Steven Kelly, President and CEO, will engage in a fireside chat on July 9, 2024, at 9:10 am ET. This session will be available via an audio webcast on the Investor Events section of Carisma's Investor Relations webpage and will remain archived for a period.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the adjournment of its annual stockholder meeting on June 13, 2024, due to technical difficulties. The meeting will reconvene virtually on June 14, 2024, at 10:00 a.m. Eastern Time. Stockholders can attend online, vote electronically, and submit questions via a virtual audio web conference.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
What does Carisma Therapeutics specialize in?
How does Carisma differentiate itself from traditional cell therapy companies?
What is the significance of Carisma's collaboration with Moderna?
What are Carisma's key therapeutic areas?
What challenges does Carisma address in cancer treatment?
What is the company's approach to fibrosis treatment?
What is the potential of Carisma's in vivo therapies?
What is the significance of Carisma's pivot to in vivo therapies?
What are the risks associated with Carisma's business model?
Where is Carisma Therapeutics headquartered?
